Organogenesis Holdings Inc. (NASDAQ:ORGO) Sees Significant Increase in Short Interest

Organogenesis Holdings Inc. (NASDAQ:ORGO) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 11,000,000 shares, an increase of 29.1% from the November 30th total of 8,520,000 shares. Based on an average daily volume of 690,900 shares, the short-interest ratio is currently 15.9 days. Approximately 16.3% of the company’s shares are short sold.

Insider Transactions at Organogenesis

In other Organogenesis news, CEO Gary S. Gillheeney sold 55,615 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $3.36, for a total transaction of $186,866.40. Following the transaction, the chief executive officer now directly owns 3,044,779 shares of the company’s stock, valued at approximately $10,230,457.44. The trade was a 1.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 278,116 shares of company stock worth $991,190. Company insiders own 36.90% of the company’s stock.

Institutional Investors Weigh In On Organogenesis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Captrust Financial Advisors purchased a new position in Organogenesis during the third quarter valued at $36,000. Delap Wealth Advisory LLC bought a new position in shares of Organogenesis in the 2nd quarter worth about $40,000. Intech Investment Management LLC purchased a new position in Organogenesis during the 3rd quarter valued at about $43,000. Allspring Global Investments Holdings LLC boosted its stake in Organogenesis by 4,989.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after acquiring an additional 15,369 shares in the last quarter. Finally, Pallas Capital Advisors LLC grew its holdings in Organogenesis by 70.8% in the third quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock worth $63,000 after purchasing an additional 9,048 shares during the period. 49.57% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Trading Down 2.7 %

Shares of ORGO opened at $3.19 on Friday. Organogenesis has a 1-year low of $2.16 and a 1-year high of $4.70. The firm has a market capitalization of $401.07 million, a price-to-earnings ratio of -53.17 and a beta of 1.73. The firm’s 50-day moving average price is $3.46 and its 200-day moving average price is $3.03. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The business had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. During the same period in the previous year, the firm posted $0.02 EPS. Sell-side analysts anticipate that Organogenesis will post -0.07 EPS for the current year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.